Arrowhead Pharmaceuticals (ARWR) Set to Announce Earnings on Tuesday

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is set to release its earnings data after the market closes on Tuesday, November 26th. Analysts expect Arrowhead Pharmaceuticals to post earnings of ($0.63) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Arrowhead Pharmaceuticals Price Performance

Arrowhead Pharmaceuticals stock opened at $19.02 on Tuesday. The stock has a fifty day moving average price of $20.06 and a two-hundred day moving average price of $23.39. Arrowhead Pharmaceuticals has a 52-week low of $17.05 and a 52-week high of $39.83. The firm has a market capitalization of $2.36 billion, a P/E ratio of -4.07 and a beta of 0.93.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ARWR. B. Riley reiterated a “buy” rating and set a $55.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 12th. Royal Bank of Canada restated an “outperform” rating and set a $42.00 target price on shares of Arrowhead Pharmaceuticals in a report on Thursday, September 26th. Piper Sandler restated an “overweight” rating and set a $62.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, October 8th. HC Wainwright restated a “buy” rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a report on Friday, October 11th. Finally, StockNews.com upgraded Arrowhead Pharmaceuticals to a “sell” rating in a report on Tuesday, November 12th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $45.33.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.